What is the current stock price of Silo Pharma, Inc. (SILO)?

As of the latest market data, Silo Pharma, Inc. (SILO) is trading at $0.44. The stock has seen a gain of 6.04% today.

Does Silo Pharma, Inc. (SILO) pay a dividend?

Based on current data, Silo Pharma, Inc. does not have a confirmed active dividend policy.

What is the market cap of Silo Pharma, Inc.?

The current market capitalization of Silo Pharma, Inc. (SILO) is approximately unavailable.

SILO

Silo Pharma, Inc.·Healthcare

0.44

6.035%(+0.03)

Market Closed

0.48

8.844%(+0.04)

After Hours

Last Updated: — ET

52W L: $0.2252W H: $1.19

SILO NEWS

benzinga.com

4d ago

Silo Pharma Rallies After Securing Key Patent Allowance

Silo said the European Patent Office issued a Rule 71(3) communication indicating its intent to grant a patent for the application, which the company has an exclusive license from Columbia University.

benzinga.com

4d ago

Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline—UnitedHealth, Silo Pharma, Phillips 66 In Focus

Meanwhile, Iran has submitted a 10-point response to the U.S. peace proposals, which a U.S. official described as "maximalist", citing the Iranian state news agency IRNA.

feeds.benzinga.com

4d ago

Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know

Silo Pharma stock jumps after-hours after European patent allowance for PTSD prevention therapy targeting 5-HT4 pathway.

globenewswire.com

5d ago

Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy

EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the European Patent Office (EPO) has issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress” (European Patent Application No. 20786878.7) that the Company has an exclusive license from Columbia University.

defenseworld.net

Mar 14

Contrasting Palvella Therapeutics (NASDAQ:PVLA) & Silo Pharma (NASDAQ:SILO)

Silo Pharma (NASDAQ: SILO - Get Free Report) and Palvella Therapeutics (NASDAQ: PVLA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk. Risk and Volatility Silo Pharma has a

globenewswire.com

Feb 23

Silo Pharma Announces Share Buyback Program

Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. The Company had 13,318,273 shares of common stock outstanding as of November 13, 2025, as reported in its Quarterly Report for the period ended September 30, 2025.

Company Profile

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2021-01-08

Beta

0.59

Websitesilopharma.com↗